Is endothelial progenitor cell dysfunction involved in altered angiogenic processes in patients with hypertension?
Hypertension represents one of the most frequent modifiable risk factors for cardiovascular disease (CVD). Despite the arrival of novel antihypertensive drugs and progress in primary prevention and screening, the improvement of blood pressure control does not similarly reduce the incidence of end-organ damage associated with hypertension. Recently, the concept of reduced angiogenesis as a new CVD risk factor has gained the interest of an increasing number of investigators in the field. Indeed, pharmacologic and stem cell-based strategies aimed to induce angiogenesis seem to improve the course of ischemic vascular disease. However, few to no reports have studied the possible therapeutic potential of angiogenesis in essential hypertension. In this review, we discuss the potential involvement of endothelial progenitor cells in modulating angiogenesis and their putative therapeutic role in improving capillary rarefaction and arterial stiffness in essential hypertensive patients.